Clinical Pharmacology & Therapeutics · 2007 · 53 citations · 30 references
PharmacyPharmacokineticsPharmacologyClinical PharmacologyPharmacokinetic VariabilityPopulation PharmacokineticsCancer PharmacogenomicsDrug DispositionInterindividual VariabilityPharmacogenetic TestingPopulation PharmacogeneticsPopulation PharmacogenomicsClinical Pharmacology EvidenceDrug Metabolism PolymorphismsGlutathione S-transferase ActivityGlutathione S-transferase-mediated MetabolismGlutathione S-transferasesInterindividual Pharmacokinetic VariabilitySerious Adverse EventsTherapeutic Drug Monitoring Biomarkers
Melphalan is associated with severe side effects such as mucositis, diarrhea, and myelosuppression. We investigated how much the individual severity of these side effects is predicted by pharmacokinetics. In addition, we studied glutathione S-transferase GSTM1, GSTT1, and GSTP1 polymorphisms in relation to adverse events. A high interindividual pharmacokinetic variability was observed in 84 patients. There was a linear correlation between creatinine and melphalan clearance (P=0.0004). Patients treated with a dose > or = 70 mg/m(2) had a 23-fold increased risk to develop mucositis (P<0.001) and a 12-fold increased risk to develop diarrhea (P<0.001) compared with lower doses. The GSTP1 codon 105 polymorphism may be relevant for development of mucositis and the GSTT1 deletion may predict diarrhea, but these findings require confirmation. Melphalan-induced side effects were significantly dependent only on dose. Therapeutic drug monitoring or genotyping for GST does not appear to be very helpful in optimizing therapy with melphalan.
30
M Ichel A Ttal, J Ean, A.A. D uuml nne et al. · 2013 · 2.2K citations
Medicine, Hematology, Oncology +14
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
J. A. Child, Gareth J. Morgan, Faith E. Davies et al. · New England Journal of Medicine · 2003 · 1.8K citations · Full text
Medicine, Hematology, Oncology +17